Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
Search results
798 results
-
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]
Proposed [GID-TA10332] Expected publication date: TBC
-
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Proposed [GID-TA10198] Expected publication date: TBC
-
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Proposed [GID-TA10336] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Proposed [GID-TA10426] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
Proposed [GID-TA10505] Expected publication date: TBC
-
Semaglutide for treating type 2 diabetes (ID1450)
Proposed [GID-TA10438] Expected publication date: TBC
-
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]
Proposed [GID-TA10297] Expected publication date: TBC
-
Pegvaliase for treating phenylketonuria [ID1110]
Proposed [GID-TA10345] Expected publication date: TBC
-
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)
Proposed [GID-TA10239] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Proposed [GID-TA10393] Expected publication date: TBC
-
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
Proposed [GID-TA10666] Expected publication date: 26 August 2021
-
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]
Proposed [GID-TA10782] Expected publication date: 20 October 2021
-
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]
Proposed [GID-TA10655] Expected publication date: TBC
-
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]
Proposed [GID-TA10676] Expected publication date: TBC
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Proposed [GID-TA10763] Expected publication date: TBC
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Proposed [GID-TA10764] Expected publication date: TBC
-
Semaglutide for managing overweight and obesity [ID3850]
Proposed [GID-TA10765] Expected publication date: TBC
-
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]
Proposed [GID-TA10704] Expected publication date: TBC
-
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Proposed [GID-TA10453] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Proposed [GID-TA10439] Expected publication date: TBC
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Proposed [GID-TA10519] Expected publication date: TBC
-
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Proposed [GID-TA10553] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Proposed [GID-TA10306] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Proposed [GID-TA10574] Expected publication date: TBC
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
Proposed [GID-TA10706] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]
Proposed [GID-TA10739] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Proposed [GID-TA10757] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Proposed [GID-TA10741] Expected publication date: TBC
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
Proposed [GID-TA10701] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Proposed [GID-TA10700] Expected publication date: TBC
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
Proposed [GID-TA10658] Expected publication date: 20 October 2021
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]
Proposed [GID-TA10654] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
Proposed [GID-TA10714] Expected publication date: TBC
-
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
Amivantamab for non-small cell lung cancer [ID3836]
Proposed [GID-TA10729] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Proposed [GID-TA10598] Expected publication date: TBC
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
Proposed [GID-TA10691] Expected publication date: TBC
-
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Proposed [GID-TA10694] Expected publication date: TBC
-
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]
Proposed [GID-TA10698] Expected publication date: TBC